Outlook Therapeutics, Inc. Research And Development Expense

• Outlook Therapeutics, Inc. showed a decrease of -34.9% in Research And Development Expense from 2024 to 2025.
• This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Outlook Therapeutics, Inc.'s Research And Development Expense has declined by 30.1%.
• Historical annual values: Fiscal year 2025: $27.18 million | Fiscal year 2024: $41.76 million | Fiscal year 2023: $26.45 million | Fiscal year 2022: $42.33 million | Fiscal year 2021: $38.96 million | Fiscal year 2020: $26.34 million | Fiscal year 2019: $23.81 million | Fiscal year 2018: $18.50 million | Fiscal year 2017: $23.81 million | Fiscal year 2016: $32.76 million | Fiscal year 2015: $38.88 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026